Stefan Boeck

7.4k total citations · 1 hit paper
145 papers, 4.3k citations indexed

About

Stefan Boeck is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Stefan Boeck has authored 145 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Oncology, 48 papers in Pulmonary and Respiratory Medicine and 42 papers in Cancer Research. Recurrent topics in Stefan Boeck's work include Pancreatic and Hepatic Oncology Research (102 papers), Cancer Genomics and Diagnostics (40 papers) and Neuroendocrine Tumor Research Advances (39 papers). Stefan Boeck is often cited by papers focused on Pancreatic and Hepatic Oncology Research (102 papers), Cancer Genomics and Diagnostics (40 papers) and Neuroendocrine Tumor Research Advances (39 papers). Stefan Boeck collaborates with scholars based in Germany, United States and Netherlands. Stefan Boeck's co-authors include Volker Heinemann, Michael Haas, Stefan Holdenrieder, Steffen Ormanns, Thomas Kirchner, Stephan Krüger, Axel Hinke, Christophe Louvet, Roberto Labianca and C. Benedikt Westphalen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Stefan Boeck

142 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Advances in cancer immunotherapy 2019 – latest trends

2019 400 citations Stephan Krüger, Steffen Ormanns et al. profile →

Peers

Countries citing papers authored by Stefan Boeck

Since Specialization

Citations

This map shows the geographic impact of Stefan Boeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Boeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Boeck more than expected).

Fields of papers citing papers by Stefan Boeck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Boeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Boeck. The network helps show where Stefan Boeck may publish in the future.

Co-authorship network of co-authors of Stefan Boeck

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Boeck. A scholar is included among the top collaborators of Stefan Boeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Boeck. Stefan Boeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer – Results of a phase 1b clinical trial 2024 ·European Journal of Cancer ·Danmei Zhang, C. Benedikt Westphalen, Michael Quante, Dirk Waldschmidt, Swantje Held, Fabian Kütting, Klara Dorman, Kathrin Heinrich, (unknown), (unknown), Michael Haas, Stefan Boeck, Volker Heinemann, (unknown)	5
2	SO-6 Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group 2023 ·Annals of Oncology ·(unknown), Volker Heinemann, Laura Fischer, Frank Gieseler, Thomas Hoehler, Julia Mayerle, D. Quietzsch, Anke Reinacher‐Schick, Michael Schenk, G. Seipelt, Jens T. Siveke, Michael Stahl, Ursula Vehling‐Kaiser, Dirk Waldschmidt, Klara Dorman, (unknown), C. Benedikt Westphalen, Michael Haas, Stefan Boeck	1
3	Abstract CT195: Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nab-paclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma 2023 ·Cancer Research ·Jens T. Siveke, Marianne Sinn, Stefan Boeck, Gabriele Margareta Siegler, Thomas Seufferlein, Joerg Trojan, Dirk Waldschmidt, Alexander Köenig, Dorothea Schipp, (unknown), (unknown), Volker Kunzmann	1
4	Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia 2022 ·Infection ·(unknown), (unknown), Lars H. Lindner, Martin Dreyling, Michael von Bergwelt‐Baildon, Stefan Boeck, Clemens Gießen-Jung, Valeria Milani, Hans‐Joachim Stemmler, Marion Subklewe, Oliver Weigert, Karsten Spiekermann	1
5	The Burden of Fear of Cancer Recurrence in Genitourinary Cancers: A Prospective Study (NCT04535921) 2022 ·Oncology Research and Treatment ·Yannic Volz, (unknown), Lennert Eismann, Friedrich Jokisch, Gerald Bastian Schulz, Boris Schlenker, Alexander Kretschmer, Michael Staehler, Stefan Boeck, Raphaela Waidelich, Alexander Büchner, Christian G. Stief, Severin Rodler	5
6	Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers 2022 ·Journal of Cancer Research and Clinical Oncology ·Klara Dorman, (unknown), Stephan Krüger, (unknown), (unknown), Alexander Rupp, Danmei Zhang, (unknown), C. Benedikt Westphalen, Michael Haas, Michael Guenther, Steffen Ormanns, Frank Klawonn, Jens Werner, Michael von Bergwelt‐Baildon, Volker Heinemann, Stefan Boeck, Stefan Holdenrieder	8
7	Rituximab Treatment of Hairy Cell Leukemia in a Patient with <b><i>Mycobacterium kansasii</i></b> Infection: A Case Report 2021 ·Oncology Research and Treatment ·(unknown), Danmei Zhang, Andreas Zimmermann, Pontus Mertsch, (unknown), (unknown), Elham Khatamzas, Steffen Ormanns, Marion Heiß-Neumann, Martin Dreyling, Michael von Bergwelt‐Baildon, Stefan Boeck	1
8	Clinical outcome of elderly patients (≥ 70 years) with esophageal cancer undergoing definitive or neoadjuvant radio(chemo)therapy: a retrospective single center analysis 2018 ·Radiation Oncology ·Franziska Walter, (unknown), Nina-Sophie Schmidt-Hegemann, (unknown), S. Gerum, Stefan Boeck, Martin K. Angele, Claus Belka, Falk Roeder	25
9	Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: A Retrospective Cohort Study 2016 ·International Journal of Surgery ·Bernhard W. Renz, (unknown), (unknown), (unknown), Tobias S. Schiergens, Hanno Nieß, Stefan Boeck, Volker Heinemann, Werner Hartwig, Jens Werner, Christiane J. Bruns, Axel Kleespies	40
10	Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater 2015 ·Surgery ·Tobias S. Schiergens, Simone Reu, Jens Neumann, Bernhard W. Renz, Hanno Nieß, Stefan Boeck, Volker Heinemann, Christiane J. Bruns, Karl‐Walter Jauch, Axel Kleespies	52
11	Complete pathological response to neoadjuvant pemetrexed/cisplatin in combination with regional hyperthermia in a patient with sarcomatoid peritoneal mesothelioma 2014 ·Anti-Cancer Drugs ·Stephan Krüger, Martin K. Angele, Simone Reu, Karl Sotlar, Anno Graser, Michael Haas, Markus Albertsmeier, Hans‐Joachim Stemmler, Volker Heinemann, Lars H. Lindner, Stefan Boeck	2
12	P-ERK, P-AKT and p53 as Tissue Biomarkers in Erlotinib-Treated Patients with Advanced Pancreatic Cancer: a Translational Subgroup Analysis From Aio-PK0104 2013 ·Annals of Oncology ·Stefan Boeck, Jens T. Siveke, Steffen Ormanns, Ruediger P. Laubender, Andreas Jung, Michael Haas, Ursula Vehling‐Kaiser, (unknown), Ludwig Fischer von Weikersthal, Michael Clemens, Thomas Gauler, Angela Märten, Stefan Klein, G. Kojouharoff, Michael Geißler, Tim F. Greten, Thomas Kirchner, Volker Heinemann	1
13	Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer 2013 ·Annals of Oncology ·Volker Heinemann, Michael Haas, Stefan Boeck	83
14	External Validation of 2 Prognostic Indices for Patients With Advanced Pancreatic Cancer Treated With First-line Therapy 2012 ·Pancreas ·Michael Haas, Ruediger P. Laubender, Christina Klose, Christoph Schulz, Ulrich Mansmann, Stefan Boeck, Volker Heinemann	1
15	EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 2012 ·British Journal of Cancer ·Stefan Boeck, Andreas Jung, Rüdiger P. Laubender, Jens Neumann, (unknown), (unknown), Ursula Vehling‐Kaiser, (unknown), Ludwig Fischer von Weikersthal, Michael Clemens, Thomas Gauler, Angela Märten, Stefan Klein, G. Kojouharoff, (unknown), Michael Geißler, Tim F. Greten, Ulrich Mansmann, Thomas Kirchner, Volker Heinemann	77
16	Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity 2011 ·The Pharmacogenomics Journal ·(unknown), Christian Schumann, Stefan Rüdiger, Stefan Boeck, Volker Heinemann, Volker Kächele, Angela Seeringer, (unknown), Thomas Seufferlein, Julia Stingl	29
17	UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer 2009 ·World Journal of Gastroenterology ·Christoph Schulz, Volker Heinemann, Andreas Schalhorn, (unknown), Thomas Zwingers, Stefan Boeck, Clemens Gießen, Hans‐Joachim Stemmler	38
18	Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer 2007 ·Annals of Oncology ·Stefan Boeck, Thomas Hoehler, G. Seipelt, Rolf Mahlberg, A. Wein, Andreas Hochhaus, (unknown), Bernd Schmid, E. Kettner, Martina Stauch, Florian Lordick, Y. Ko, Michael Geißler, (unknown), G. Kojouharoff, Alexander Golf, (unknown), Volker Heinemann	59
19	Importance of performance status for treatment outcome in advanced pancreatic cancer 2007 ·World Journal of Gastroenterology ·Stefan Boeck	54
20	Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer 2007 ·Anti-Cancer Drugs ·Stefan Boeck, Andreas Hausmann, Roland Reibke, Christoph Schulz, Volker Heinemann	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact